Kymera Investor Presentation Deck

KYMERA %hCD45+ in PB ● 100 ● 80 60 40 20 0 Strong Single Agent and Combinatorial Activity in Venetoclax Resistant AML Models Whole Blood DFAM-68555 Day 14 Vehicle KT-253 3.0mg/kg Q3W Venetoclax 100mg/kg QD O Study Day DFAM-6855 Characteristics: M5a (monoblastic); Mutations: FLT3, MLL3 KT-253 3 mg/kg Q3W dosing significantly reduces hCD45+ cells in Peripheral Blood 14 ©2023 KYMERA THERAPEUTICS, INC. Tumor Volume (mm³) Mean ± SEM 2000 1500 1000 500 ● 0 MOLM-13 AML XGs Vehicle IV KT-253 1 mg/kg IV Q3W Venetoclax 100 mg/kg PO QD KT-253 1 mg/kg plus Venetoclax 7 14 Days (Post-randomization) 21 1 28 Single dose of KT-253 in combination with daily dosing of Venetoclax achieves sustained tumor regression in MOLM- 13 xenograft model PAGE 56

View entire presentation